DIRS.INFO The most relevant business & tech news

☆ We're raising our price target on Eli Lilly by $120 after its excellent quarter
▼ + stars: | 2024-02-06 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +10 min

Bottom line Eli Lilly delivered a strong report Tuesday. Still, it's not a surprise to see shares of Eli Lilly fall nearly 2% Tuesday, to around $694 each. Despite doubling manufacturing capacity year over year in 2023, Eli Lilly said demand for its GLP-1s is "likely to outpace supply" this year. We're raising our Eli Lilly price target to $750 a share from $630, while reiterating our 2 rating on the stock, meaning we'd wait for a pullback before adding to our position. Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023.

Persons: Eli Lilly's, Lilly's, Eli Lilly, Mounjaro, Zepbound, it's, —, Jim Cramer, Anat Ashkenazi, NASH, Lilly, Jim, Jardiance, Verzenio, Trulicity, donanemab, Ashkenazi, Jim Cramer's, George Frey Organizations: Revenue, LSEG, U.S, Novo Nordisk, Food and Drug Administration, Analysts, Investors, FDA, CNBC, Bloomberg, Getty Locations: Mounjaro's, U.S, Mounjaro, Trulicity, Provo , Utah

☆ Mounjaro is more effective than Ozempic for weight loss in overweight and obese adults, real-world study says
▼ + stars: | 2023-11-27 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The blockbuster diabetes drug Mounjaro is more effective for weight loss than another highly popular treatment, Ozempic, in overweight or obese adults, according to a large analysis of real-world data published Monday. The results come as both drugs and similar treatments approved for weight loss soar in demand in the U.S. for their ability to help patients shed unwanted pounds over time. Previous head-to-head studies have similarly suggested that Mounjaro is more effective than Ozempic for weight loss and controlling blood sugar in adults with Type 2 diabetes. But Monday's study confirms Mounjaro's edge over Ozempic in a real-world setting, specifically among adults who are overweight or obese. Eli Lilly is pitting Mounjaro against Wegovy, a higher-dose version of Ozempic approved for weight loss, in an ongoing clinical trial in obese or overweight patients.

Persons: Eli Lilly, Mounjaro, We've, Nick Stucky Organizations: Novo Nordisk, Truveta Research, Research, Wegovy Locations: U.S

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. The company declined to comment on the plans but news conferences are planned in Alzey, where sources say the plant will be built, and Berlin on Friday. Other people familiar with the plans told Reuters that at least 1,000 jobs would be created. Eli Lilly said it would unveil "far-reaching investment plans" at Friday's news conference, which will be attended by Germany's economy and health ministers. Mounjaro's success helped Lilly post a 37% gain in third-quarter revenues to $9.5 billion, topping Wall Street estimates.

Persons: Eli Lilly, Mike Segar, Mounjaro, TSMC, Lilly's, Lilly, Rene Wagner, Klaus Lauer, Andreas Rinke, Ludwig Burger, Thomas Escritt, Madeline Chambers, Miranda Murray, Christina Fincher Organizations: Company, REUTERS, Basf, Reuters, BASF, U.S ., U.S, Intel, European Union, Novo Nordisk, U.S . Food, Drug Administration, Thomson Locations: Branchburg , New Jersey, BERLIN, Germany, Alzey, Berlin, U.S, Ukraine, European, Indianapolis, Danish, Eisai

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo Acquire Licensing RightsBERLIN, Nov 15 (Reuters) - U.S. pharma company Eli Lilly (LLY.N) plans an investment in the single-digit billion dollar range in a new plant in western Germany, people familiar with the matter told Reuters after the company called a news conference for Friday. Eli Lilly said it would unveil "far-reaching investment plans" at Friday's news conference, which will be attended by Germany's economy and health ministers. Mounjaro's success helped Lilly post a 37% gain in third-quarter revenues to $9.5 billion, topping Wall Street estimates. The group's market value has ballooned to around $580 billion, up more than 65% so far this year.

Persons: Eli Lilly, Mike Segar, Mounjaro, TSMC, Lilly's, Lilly, Rene Wagner, Klaus Lauer, Ludwig Burger, Thomas Escritt, Chizu Nomiyama, Jane Merriman Organizations: Company, REUTERS, Rights, . pharma, Reuters, U.S ., U.S, Intel, European Union, Novo Nordisk, U.S . Food, Drug Administration, Thomson Locations: Branchburg , New Jersey, Germany, Rhineland, Palatinate, U.S, Ukraine, European, Indianapolis, Danish, Eisai

☆ Exclusive: Lilly hires CordenPharma to make diabetes drug Mounjaro's active ingredient -source
▼ + stars: | 2023-10-19 | by ( Maggie Fick | ) www.reuters.com time to read: +3 min

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo Acquire Licensing RightsLONDON, Oct 19 (Reuters) - Eli Lilly (LLY.N) has hired Switzerland-based contract drugmaker CordenPharma to produce the active ingredient in its diabetes drug Mounjaro, a source familiar with the matter told Reuters on Thursday. Lilly has said it expects U.S. approval for Mounjaro for weight loss by the end of the year. The source told Reuters that CordenPharma's factory in Colorado is under contract to make tirzepatide, the active ingredient in the weekly injection. Analysts estimate the obesity market could be worth as much as $100 billion in the next decade.

Persons: Eli Lilly, Mike Segar, drugmaker, CordenPharma, Lilly, Corden, Maggie Fick, Josephine Mason, Bill Berkrot Organizations: Company, REUTERS, Reuters, CordenPharma, Novo Nordisk, Mounjaro, Thomson Locations: Branchburg , New Jersey, Switzerland, United States, Colorado, Basel, Europe, Boulder , Colorado, Boulder

☆ Cramer says investors should stick with oil firm Pioneer amid acquisition report
▼ + stars: | 2023-10-06 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a Morning Meeting livestream at 10:20 a.m. But Jim Cramer said selling stocks on an economy that's putting many people to work, with little wage inflation, makes no sense. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Jim, Scott Sheffield's, Eli Lilly, BofA, Lilly's, Jim Cramer's Organizations: CNBC, Labor Department, Federal Reserve, Street, Exxon Mobil, Natural Resources, Eli Lilly Bank of America Locations: U.S

☆ Analysis: Wegovy launch in UK may underline Novo's need to get ahead of Lilly
▼ + stars: | 2023-09-10 | by ( Maggie Fick | ) www.reuters.com time to read: +5 min

A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August31, 2023. Studies have demonstrated more weight loss than with Wegovy. Novo's type 2 diabetes drug Ozempic has been on the market in Britain since 2019. A Lilly spokesperson declined to comment on Wegovy's launch or when exactly it would launch Mounjaro for diabetes treatment. Studies have shown that, used alongside exercise and lifestyle changes, Wegovy led to 15% weight loss over 68 weeks, while Mounjaro led to more than 22% over 72 weeks.

Persons: Victoria Klesty, Eli Lilly's, Wegovy, Lars Fruergaard Jorgensen, Novo, Lilly, Mounjaro, Ozempic, Eli Lilly, Maggie Fick, Alexander Smith, Catherine Evans Organizations: REUTERS, Wegovy, Economic Co, Development, Reuters, National Health Service, stoke, NHS, Britain's Department of Health, Social Care, Diabetes, UBS, Novo, Thomson Locations: Oslo, Norway, August31, Victoria, Britain, British, Danish, United States, Denmark, Germany, Europe, England

☆ We're optimistic about this struggling entertainment stock despite an expected weak quarter
▼ + stars: | 2023-08-09 | by ( Morgan Chittum | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Back-to-back losses Still believe in Disney Eli Lilly keeps going 1. Eli Lilly keeps going Eli Lilly (LLY) continued its post-earnings rally, up more than 1% during Wednesday trading. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

Persons: Jim Cramer, Eli Lilly, Bob Iger's, LLY, Lilly, Jim Cramer's, Jim Organizations: CNBC, Federal, Fed, Disney Disney, CNBC –, Disney's ESPN, Penn Entertainment, Regulators Locations: U.S

☆ Promise around Eli Lilly's expected obesity drug, great earnings adds some $60 billion in market cap
▼ + stars: | 2023-08-08 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +9 min

(When excluding one-time divestment contributions and last year's Covid antibody revenue, Lilly's sales rose 22% on an annual basis.) Eli Lilly shares soared more than 16% to a new all-time high during Tuesday's session. LLY YTD mountain Eli Lilly's stock performance so far in 2023. Eli Lilly now expects adjusted earnings per share between $9.70 and $9.90, up significantly from the old guidance between $8.65 and $8.85. For its part, Eli Lilly is also studying Mounjaro's impact on other health outcomes including cardiovascular events.

Persons: Eli Lilly, Mounjaro, —, Jim Cramer's, Jim, Lilly's, Cheplapharm —, Lilly, Anat Ashkenazi, Ashkenazi, Eli Lilly's, Lilly Diabetes, Michael Mason, Mason, Verzenio, Trulicity, we've, David Ricks, Jim Cramer, Cristina Arias Organizations: Novo Nordisk, U.S, Amphastar Pharmaceuticals, Management, CNBC, Company, Pharmaceutical Locations: Indianapolis, North Carolina, U.S, Trulicity, Danish, Novo, Alcobendas, Madrid, Spain

☆ Eli Lilly raises full-year guidance as drug pipeline drives second-quarter profit up 85%
▼ + stars: | 2023-08-08 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eli Lilly also increased its adjusted earnings guidance to a range of $9.70 to $9.90 per share for the year, up from a range of $8.65 to $8.85. Shares of Eli Lilly jumped 9% in premarket trading Tuesday. Last month, Eli Lilly filed for Food and Drug Administration approval of the injection for chronic weight management. Eli Lilly said it "has experienced and continues to expect intermittent delays fulfilling orders of certain Mounjaro doses given significant demand." Eli Lilly also reported no sales from its Covid-19 antibody treatments, compared with $129 million in the second quarter of 2022.

Persons: Eli Lilly, Here's, Alimta, Alimta's Organizations: Getty, Refinitiv, Food and Drug, Amphastar Pharmaceuticals, Drug Administration, . Pipeline Locations: U.S

☆ Here's what is behind the stock market's selloff and what we're doing about it
▼ + stars: | 2023-08-08 | by ( Morgan Chittum | ) www.cnbc.com time to read: +3 min

Eli Lilly surges Club name Eli Lilly (LLY) skyrocketed more than 16% on hopes for Mounjaro's use to prevent major cardiovascular events. As for strong earnings, which also helped the stock, Eli Lilly had a great quarter and raised full-year guidance. Since Friday's 8% loss on a competitor's misfortunate, PANW shares have been down Monday and now Tuesday as well. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Stocks, Eli Lilly, Moody's, Dow, Morgan Stanley, selloff, Mounjaro, Jim Cramer's, Jim Organizations: CNBC, Nasdaq, Club, Energy, Novo Nordisk, Palo, Alto Networks, JPMorgan Locations: Stocks, Wells Fargo, Novo, .

☆ Obesity is a chronic disease. It's why treating it will be so profitable unless payers push back
▼ + stars: | 2023-04-30 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Lilly manufactures tirzepatide, which is sold under the brand name Mounjaro as a type 2 diabetes treatment. It's the chronic nature of obesity that will make these drugs so profitable, analysts have said. Huynh increased his target due to higher expectations for Mounjaro sales this year. Huynh boosted his prediction for the drug's sales this year to $3.7 billion from an prior estimate of $2.7 billion. "$48 billion is a monster number," Holz said, referring to an annual sales estimate that Bank of America has floated for future Mounjaro sales.

☆ Morgan Stanley's case for six Club names, including Alphabet and Microsoft
▼ + stars: | 2023-03-21 | by ( Paulina Likos | ) www.cnbc.com time to read: +6 min

In a research note Tuesday, Morgan Stanley identified its "best long-term picks" for 2025, in line with our approach for assessing companies. Six names on Morgan Stanley's list were Club holdings, all of which the firm rated a buy. Alphabet (GOOGL): Morgan Stanley analysts think artificial intelligence (AI) will create a new growth opportunities at Google parent Alphabet in its core products, including its search engine, YouTube and cloud offerings. Morgan Stanley has price target of of $135 per share on the stock. Eli Lilly (LLY): The pharmaceuticals giant is well-positioned within the U.S. due to its strong pipeline of drugs and "robust new product cycles," Morgan Stanley analysts argued.

☆ Here’s our fourth-quarter earnings report card for all the stocks in our portfolio
▼ + stars: | 2023-03-10 | by ( Zev Fima | ) www.cnbc.com time to read: +20 min

Fourth-quarter earnings season is in the rearview mirror and most Club stocks reported results ahead of, or in line with, analysts' forecasts. Moreover, excluding foreign exchange fluctuations, this marked the ninth quarter in a row of 20% or better annual earnings growth. Nvidia (NVDA) reported a very strong quarter and better-than-expected guidance for the current quarter . Eli Lilly 's (LLY) fourth-quarter results came up a bit short on revenue but delivered a strong bottom line. Despite missing on top-line expectations, Wells Fargo 's (WFC) earnings came in better-than-expected, as the bank realized the benefits of higher interest rates .

☆ Jim Cramer's Investing Club meeting Monday: Fed and jobs, China reopening, Eli Lilly
▼ + stars: | 2023-03-06 | by ( Paulina Likos | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Fed and jobs report Stocks were trading higher Monday as investors look ahead to Federal Reserve commentary and new economic data later this week. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ Eli Lilly investors spooked by weak Mounjaro sales, but it's the obesity drug approval that will unlock its value
▼ + stars: | 2023-02-02 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +5 min

Lilly said slightly more than 50% of commercial and Part D subscribers have access to the drug via their insurance plans. But new classes of weight loss medications are helping to change this mindset. Still, legislation will be necessary to get coverage of Mounjaro for obesity and overweight treatment by Medicare plans. By law, these plans are banned from paying for weight loss medications. Wegovy and Mounjaro One encouraging sign: Lilly competitor Novo Nordisk has gained access to more than 80% of insurance company formularies for their obesity treatment, Wegovy.

☆ Eli Lilly's post-earnings decline is creating a buying opportunity for long-term investors
▼ + stars: | 2023-02-02 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Eli Lilly (LLY) reported mixed fourth-quarter results Thursday morning, but we're looking through the stock's post-earnings sell-off because there's no change to the pharmaceutical giant's bright long-term potential. Bottom line There's definitely some noise surrounding Eli Lilly's results, including sales of its key diabetes drug Mounjaro. Eli Lilly began its rolling submission to the FDA in late 2022. None of them undercut the multiyear Eli Lilly investment story, making Thursday's stock sell-off an attractive buying opportunity. It is a "very complicated" process to make that kind of drug, Ricks said, so it cannot just scale up overnight.

☆ What to watch for when 9 Club holdings report earnings on Thursday
▼ + stars: | 2023-01-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +11 min

So far, earnings season has been mixed — we've seen some strong results from Club holdings Morgan Stanley (MS) and Halliburton (HAL). Projected revenue: $4.58 billion Projected EPS: $1.30 Conference call at 9:30 a.m. Projected revenue: $7.33 billion Projected EPS: $1.81 Conference call at 10 a.m. Projected revenue: $9.26 billion Projected EPS: $2.51 Conference call at 8:30 a.m. Projected revenue: $121.19 billion Projected EPS: $1.94 Conference call at 5 p.m.

☆ Jim Cramer's Investing Club meeting Monday: Industrials, buying tech, Eli Lilly
▼ + stars: | 2022-12-19 | by ( Krystal Hur | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Still bullish on Eli Lilly The Food and Drug Administration (FDA) added Eli Lilly 's (LLY) new type-2 diabetes drug Mounjaro to its list of drugs in short supply , highlighting strong demand for the medication. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ Jim Cramer's top 10 things to watch in the market Thursday: Fed selling, chip stocks boost, Disney concern
▼ + stars: | 2022-12-15 | by ( Jim Cramer | ) www.cnbc.com time to read: +4 min

Barclay's raises price target on Club holding Wynn Resorts (WYNN) to $95 per share from $75; keeps an equal weight (hold) rating. Citi raises price target on Club holding Linde (LIN) to $402 per share from $322; keeps buy rating. HSBC starts Club stock Nvidia (NVDA) with a reduce rating and a $136-per-share price target; says downside not priced in. Cowen downgrades JetBlue (JBLU) to market perform from outperform (hold from buy); trims price target to $10 per share from $9. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ Eli Lilly's bleak annual forecast overshadows quarterly beat
▼ + stars: | 2022-11-01 | by ( ) www.reuters.com time to read: +2 min

The company's shares fell nearly 4% in premarket trading as a forecast cut for the third time this year overshadowed strong performance by its newly approved diabetes drug. The drugmaker also trimmed its full-year revenue forecast, citing a $300 million hit to its revenue from the strong dollar. Lilly now sees revenue in the range of $28.5 billion to $29 billion, below analysts' estimates of $28.76 billion at mid-point. Lilly flagged a total impact of about $1 billion from the strong dollar for the full year. The company posted better-than-expected results for the third quarter, as demand for its recently approved diabetes drug, Mounjaro, helped counter declining sales of its diabetes and cancer treatments.

☆ Eli Lilly's guidance cut is about the strong dollar, not weakening fundamentals, CEO says
▼ + stars: | 2022-11-01 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +5 min

Eli Lilly — which generates about 40% of its sales overseas — largely attributed the guidance cut to the strong U.S. dollar. With three quarters already reported, Eli Lilly now expects full-year sales to range between $28.5 billion to $29 billion and adjusted per-share earnings between $7.70 to $7.85. New diabetes drug off to great start One of our biggest reasons for liking Eli Lilly is the company's new type 2 diabetes drug that's also shown promise as an obesity treatment . The drug is similar to one that Eli Lilly is working to treat the most common form of dementia. David Ricks, CEO, Eli Lilly Scott Mlyn | CNBC

☆ Eli Lilly's growth tied to nascent diabetes drug sales
▼ + stars: | 2022-10-31 | by ( ) www.reuters.com time to read: +2 min

Oct 31 (Reuters) - Wall Street analysts will be focusing on sales of Eli Lilly and Co's (LLY.N) newly approved diabetes drug Mounjaro when the company reports results on Tuesday, as sales of its older drugs come under pressure from increased competition and low pricing. The company's sales could quickly jump once Lilly gets more insurers to cover its costs, according to Risinger. Analysts expect Mounjaro sales of $81 million in the third quarter, months into its U.S. launch, according to Refinitiv data. Lilly's sales are expected to increase to $30.23 billion in 2023, versus reported sales of $24.54 billion in 2021, with Mounjaro expected to bring in $1.34 billion in sales and become the company's third-biggest selling drug, according to Refinitiv data. Growth from older drugs such as Humalog and Alimta has slowed downTHE FUNDAMENTALS** Q3 sales expected to grow 1.8% to $6.89 billion.

Search resuls for: "Mounjaro's"

23 mentions found